World Parkinson’s Day 2025: Advancing Parkinson’s Research with Cutting-Edge Mouse Models
April 11th marks World Parkinson’s Day, honoring James Parkinson, the pioneering physician who first systematically described the disease carrying his namesake. Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting millions worldwide, primarily impairing motor functions and often accompanied by cognitive decline. As the second most common neurodegenerative disease globally, its prevalence is projected to double by 2050, reaching more than 25 million patients. This growth underscores the urgent need for breakthroughs in understanding and treating PD.
Why Parkinson’s Research Matters
Parkinson’s disease is characterized by the degeneration of dopamine-producing neurons in the substantia nigra and the accumulation of abnormal α-synuclein aggregates (Lewy bodies). Current treatments, such as levodopa and dopamine agonists, address symptoms to an extent but fail to prevent disease onset or halt disease progression. Novel therapeutic approaches—including stem cell therapy, gene editing, and nanotechnology—are critical to transforming patient outcomes and improving prognoses.
How GemPharmatech Help Your Innovation
At GemPharmatech, we are committed to accelerating PD research with advanced mouse models that replicate the complex factors underpinning the disease. Our models provide researchers access to powerful tools to investigate pathogenesis, test novel therapies, and evaluate safety using translationally-relevant tools that mimic key features of the human condition.
Our Flagship PD Models
1. B6-hSNCA-A53T Transgenic Mouse
● Key Features:
Early-onset motor dysfunction (starting at 2 months).
Detectable human α-synuclein and p-S129 α-synuclein expression.
● Why It Stands Out:
Ideal model for studying progressive α-synuclein aggregation and early therapeutic intervention.
2. B6-hSNCA-E46KA53T Double Mutant Mouse
● Key Features:
Earlier α-synuclein aggregation (starting at 1 month) and more severe motor deficits.
Extended evaluation window (1–2 months longer than single-mutant models).
● Why It Stands Out:
Mimics rapid disease progression, offering a robust platform for drug efficacy testing.
3. B6-Tfam-flox/Slc6a3-Cre Conditional Knockout Mouse
● Key Features:
Loss of dopaminergic neurons in the substantia nigra by 1 month.
Reduced dopamine levels and motor dysfunction by 2 months.
● Why It Stands Out:
Perfect for investigating mitochondrial dysfunction and its role in PD pathogenesis.
4. 6-OHDA-Induced PD Mouse Model
● Key Features:
Rapid induction of PD-like symptoms (within 4 weeks) with ~70% success rate.
Behavioral deficits (e.g., rotational bias, motor impairment) and dopaminergic neuron loss.
● Why It Stands Out:
A cost-effective, acute model for screening neuroprotective compounds.
Why Choose Gempharmatech?
● Precision: Our models replicate the multifaceted pathology of PD, from α-synuclein aggregation to mitochondrial dysfunction.
● Efficiency: Accelerate your research with accessible, reliable, and reproducible models designed for commercial drug development.
● Flexibility: Choose from progressive transgenic models or acute chemically induced models to suit your study needs.
Embark On A Journey With Us
Join GemPharmatech as we pioneer the path to breakthroughs in Parkinson’s disease research. Together, let’s explore, innovate, and redefine the future of PD treatment. Your journey starts here—because every discovery begins with a step forward.
Contact Us Today: sales@gempharmatech.com